Modulation of CCR2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial

Arthritis and Rheumatism

Volumn 58, Issue 7, 2008, Pages 1931-1939

  Vergunst, Clarissa E ^a   Gerlag, Daniëlle M ^a   Lopatinskaya, Luba ^g   Klareskog, L ^b   Smith, M D ^c   Van Den Bosch, F ^d   Dinant, Huib J ^a   Lee, Yih ^e,f   Wyant, Timothy ^e,f   Jacobson, Eric W ^e,f   Baeten, Dominique ^a,d   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Synta Pharmaceuticals Corp   (United States)

^f MILLENNIUM PHARMACEUTICALS INC   (United States)

^g Millennium Pharmaceuticals Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR2; METHOTREXATE; MLN 1202; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTHROSCOPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXICITY; KRUSKAL WALLIS TEST; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SYNOVITIS; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WILCOXON SIGNED RANKS TEST;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR2; SYNOVIAL MEMBRANE;

EID: 47249109824     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23591     Document Type: Article

References (36)

1. Vergunst CE, van de Sande MG, Lebre MC, Tak PP. The role of chemokines in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 2005;34:415-25.
2. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? [review]. Arthritis Rheum 2005;52:710-21.
3. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
4. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? [review]. Ann Rheum Dis 2004;63:1186-94.
5. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J Immunol 1995;155:3610-8.
6. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997;40:217-25.
7. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? [review]. Arthritis Rheum 1997;40:5-18.
8. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
9. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
10. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007;56:3869-71.
11. Katschke KJ Jr, Rottman JB, Ruth JH, Qin S, Wu L, LaRosa G, et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44:1022-32.
12. Haringman JJ, Smeets TJ, Reinders-Blankert P, Tak PP. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 2006;65:294-300.
13. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J 1994;8:1055-60.
14. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
15. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, et al. The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 2005;83:672-81.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
19. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
20. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992;5:119-29.
21. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
23. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
24. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
25. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005;7:R862-7.
26. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor a blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
27. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21.
28. 99mTc-hmpao scintigraphy [abstract]. Arthritis Rheum 2005;52Suppl 9:S321.
29. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Van den Bosch F, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2387-92.
30. De Groot J, te Koppele JM, Tak PP. Biological markers. In: Harris ED Jr, Budd RC, Firestein GS, Genovese M, Sergent JS, Ruddy S, editors. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier Saunders; 2004. p. 728-38.
31. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8.
32. Vergunst CE, Gerlag DM, Dinant HJ, Schulz L, Vinkenoog M, Smeets TJ, et al. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 2007;12:1773-8.
33. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007;117:902-9.
34. Beaulieu A, Hasler F, Martin Mola E, Pavelka K, DeMartino J, Struthers M, et al. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis [abstract]. Ann Rheum Dis 2006;65(Suppl II):175.
35. + T cells. J Immunol 2004;172:890-8.
36. Shahrara S, Proudfoot AE, Woods JM, Ruth JH, Amin MA, Park CC, et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005;52:1907-19.